前言:一篇好文章的誕生,需要你不斷地搜集資料、整理思路,本站小編為你收集了豐富的人大副主任述職報(bào)告主題范文,僅供參考,歡迎閱讀并收藏。
【關(guān)鍵詞】 川芎嗪注射液; 腹膜間皮細(xì)胞; 高糖; ⅰ型膠原; 基質(zhì)金屬蛋白酶?1; 基質(zhì)金屬蛋白酶抑制劑?1; 體外實(shí)驗(yàn)
zhu gs, he js. j chin integr med. 2009; 7(1): 65?69.
received june 18, 2008; accepted july 22, 2008; published online january 15, 2009.
indexed/abstracted in and full text link?out at pubmed. journal title in pubmed: zhong xi yi jie he xue bao.
free full text (html and pdf) is available at .
forward linking and reference linking via crossref.
doi: 10.3736/jcim20090110open access
effects of ligustrazine injection on high glucose?induced type ⅰ collagen, matrix metalloproteinase?1 and tissue inhibitor of metalloproteinase?1 expressions in human peritoneal mesothelial cells in vitro
gui?song zhu, jin?song he
department of nephrology, the affiliated drum tower hospital, nanjing university medical school, nanjing, jiangsu province 210008, china
objective: to investigate the effects of ligustrazine injection on type ⅰ collagen, matrix metalloproteinase?1 (mmp?1) and tissue inhibitor of metalloproteinase?1 (timp?1) expressions in human peritoneal mesothelial cells (hpmcs) cultured in high glucose conditions.
methods: hpmcs were isolated from human omenta by trypsin digestion method and subcultured. then, the hpmcs were divided into normal control group, high glucose group and high glucose plus low?, medium? and high?dose ligustrazine (10, 20 and 40 mg/l ligustrazine respectively) groups. semi?quantitative reverse transcription?polymerase chain reaction was used to detect the expressions of type ⅰ collagen, mmp?1 and timp?1 mrnas in hpmcs. proteins of type ⅰ collagen, mmp?1 and timp?1 in culture supernatants were measured by enzyme?linked immunosorbent assay (elisa). cell protein concentration was measured by trace bicinchoninic acid method to correct the elisa assay results.
results: ligustrazine injection could significantly decrease high glucose?induced type ⅰ collagen and timp?1 expressions in a dose?dependent manner both in protein and gene levels (p<0.05, p<0.01). in addition, medium? and high?dose ligustrazine injection could significantly increase mmp?1 expression which was inhibited by high glucose concentrations (p<0.05).
conclusion: ligustrazine injection does not only decrease type ⅰ collagen synthesis, but also promote its degradation by modulating unbalanced mmp?1/timp?1 expression in hpmcs cultured in high glucose conditions.
keywords: ligustrazine injection; human peritoneal mesothelial cells; high glucose; type ⅰ collagen; matrix metalloproteinase?1; tissue inhibitor of metalloproteinase?1; in vitro
腹膜纖維化是腹膜透析治療的主要并發(fā)癥,最終導(dǎo)致腹膜功能衰竭,這是腹膜透析患者退出治療的主要原因[1]。腹膜纖維化以細(xì)胞外基質(zhì)(extracellular matrix, ecm)的過度沉積為特點(diǎn)[2]。研究表明,ecm的過度沉積是由于ecm合成與降解失衡而引起[3]。ⅰ型膠原是腹膜纖維化中主要的ecm[4],其降解過程受基質(zhì)金屬蛋白酶?1(matrix metalloproteinase?1, mmp?1)及其特異性抑制劑金屬蛋白酶組織抑制劑?1(tissue inhibitor of metalloproteinase?1, timp?1)調(diào)控[5]。有研究證實(shí),高糖能上調(diào)腹膜間皮細(xì)胞(human peritoneal mesothelial cells, hpmcs)ⅰ型膠原和timp?1的表達(dá),降低mmp?1活性[3]。本研究通過觀察川芎嗪注射液對高糖刺激下hpmcs ⅰ型膠原、mmp?1和timp?1表達(dá)的影響,探討川芎嗪在防治腹膜纖維化中的作用及其機(jī)制。
1 材料和方法
1.1 試劑和主要儀器 川芎嗪注射液(江蘇蘇中藥業(yè)集團(tuán)股份有限公司,批準(zhǔn)號為國藥準(zhǔn)字h20020630);50%葡萄糖注射液(江蘇方強(qiáng)制藥廠,批號為200710111)。磷酸鹽緩沖液(phosphate buffered solution, pbs)、胎牛血清(fetal calf serum, fcs)、trizol和rpmi?1640粉劑等(gibco公司);胰蛋白酶和瓊脂糖粉等(promega公司);ⅰ型膠原、mmp?1和timp?1酶聯(lián)免疫吸附測定(enzyme?linked immunosorbent assay, elisa)試劑盒(adl公司);二喹啉甲酸(bicinchoninic acid, bca)蛋白含量檢測試劑盒(南京凱基生物科技公司);ⅰ型膠原、mmp?1、timp?1和β?actin引物,m?mlv第一鏈cdna合成試劑盒和taq酶等(invitrogen公司);抗細(xì)胞角蛋白抗體、抗細(xì)胞波形蛋白抗體、第ⅷ因子抗體和抗白細(xì)胞cd45抗體(北京中山生物技術(shù)有限公司)。nu?2500e二氧化碳培養(yǎng)箱(nuaire公司);全自動酶標(biāo)儀(biobank公司);生物電泳圖像分析系統(tǒng)(上海復(fù)日科技有限公司)。
1.2 實(shí)驗(yàn)方法
1.2.1 hpmcs的培養(yǎng)與鑒定 取來自南京大學(xué)醫(yī)學(xué)院附屬鼓樓醫(yī)院普外科擇期腹部手術(shù)患者(排除尿毒癥、腹膜炎)捐獻(xiàn)的大網(wǎng)膜組織,按文獻(xiàn)[3]方法原代培養(yǎng)hpmcs,按1?3傳代,第3代細(xì)胞用于實(shí)驗(yàn),每次實(shí)驗(yàn)均由來自3個(gè)患者的標(biāo)本進(jìn)行3次獨(dú)立實(shí)驗(yàn)。倒置相差顯微鏡觀察hpmcs呈多邊形,似鋪路鵝卵石樣外觀;免疫組化鑒定抗細(xì)胞角蛋白抗體和抗波形蛋白抗體染色陽性,抗第ⅷ因子抗體和抗白細(xì)胞cd45抗體染色陰性。
1.2.2 實(shí)驗(yàn)步驟和分組 hpmcs用含1%fcs的rpmi?1640培養(yǎng)液同步培養(yǎng)24 h后分為5組(每組設(shè)3個(gè)樣本):正常組(完全培養(yǎng)液)、高糖對照組(2.5%葡萄糖)和高糖(2.5%葡萄糖)加低、中、高劑量川芎嗪(10、20和40 mg/l)組。各組完全培養(yǎng)液均為含有15% fcs的rpmi?1640培養(yǎng)液。細(xì)胞置于37 ℃、5% co2培養(yǎng)箱培養(yǎng)48 h。
1.2.3 elisa法檢測細(xì)胞上清液中ⅰ型膠原、mmp?1和timp?1含量 分組干預(yù)48 h后,離心收集上清液,按elisa試劑盒說明書檢測ⅰ型膠原、mmp?1和timp?1表達(dá)水平。用0.1 mol/l naoh溶解細(xì)胞沉淀,bca蛋白檢測試劑盒測定細(xì)胞沉淀中蛋白質(zhì)濃度,用相應(yīng)蛋白質(zhì)濃度結(jié)果校正檢測結(jié)果。
1.2.4 半定量rt?pcr 分組處理同上。采用trizol一步法提取總rna,2 μg總rna進(jìn)行逆轉(zhuǎn)錄合成cdna,50 μl反應(yīng)體系進(jìn)行pcr擴(kuò)增,以β?actin作內(nèi)參照(引物序列及反應(yīng)條件見表1)。1.5%瓊脂糖凝膠電泳(110 v,15 min)進(jìn)行pcr產(chǎn)物鑒定,電泳圖像分析儀掃描分析,mrna相對含量用其pcr產(chǎn)物吸光值(absorance, a)與β?actin a值的比值表示。引物及pcr反應(yīng)條件見表1。
1.3 統(tǒng)計(jì)學(xué)方法 實(shí)驗(yàn)數(shù)據(jù)用x±s表示,采用spss 15.0軟件進(jìn)行統(tǒng)計(jì)分析,組間差異比較采用單因素方差分析,兩組間均數(shù)比較采用lsd?t檢驗(yàn)。檢驗(yàn)水準(zhǔn)α=0.05。 表1 ⅰ型膠原、mmp?1、timp?1和β?actin引物序列及pcr反應(yīng)條件
2 結(jié) 果
2.1 上清液中ⅰ型膠原、mmp?1和timp?1蛋白質(zhì)水平 與正常組比較,高糖對照組上清液中ⅰ型膠原和timp?1含量顯著升高(p<0.01),mmp?1含量顯著下降(p<0.01);與高糖對照組比較,低、中和高劑量川芎嗪組上清液中的ⅰ型膠原和timp?1含量顯著降低(p<0.05, p<0.01),且兩者均呈量效關(guān)系,中、高劑量川芎嗪組上清液mmp?1含量顯著增加(p<0.01)。見表2。表2 各組上清液中ⅰ型膠原、mmp?1和timp?1蛋白質(zhì)表達(dá)
2.2 hpmcsⅰ型膠原、mmp?1和timp?1 mrna的表達(dá) 與正常組比較,高糖對照組hpmcs ⅰ型膠原/β?actin mrna和timp?1/β?actin mrna分別上升(15.43±0.83)倍和(4.19±0.09)倍(p<0.01),mmp?1/β?actin mrna下降(86.9±0.44)%(p<0.01);與高糖對照組相比,低、中、高劑量川芎嗪組ⅰ型膠原/β?actin mrna和timp?1/β?actin mrna表達(dá)水平均顯著下調(diào)(p<0.05),兩者均呈量效關(guān)系,中、高劑量川芎嗪組mmp?1/β?actin mrna表達(dá)顯著增加(p<0.05)。見圖1和圖2。
3 討 論
高糖透析液導(dǎo)致ecm過度沉積是腹膜纖維化的病理基礎(chǔ)[2],研究表明,高糖不僅增加hpmcsⅰ型膠原的表達(dá),并且引起ⅰ型膠原降解酶系mmp?1/timp?1的表達(dá)失衡[3]。我們的研究結(jié)果與之基本相同,此外我們發(fā)現(xiàn),川芎嗪能顯著對抗高糖的上述作用。
在生理?xiàng)l件下,hpmcs可以產(chǎn)生一定量的ecm和mmps/timps[3, 6]。mmps是降解ecm的蛋白水解酶系,幾乎能降解全部ecm成分。timps是內(nèi)源性分泌蛋白,作為mmps的特異性抑制因子,其n'端可與相應(yīng)的mmps催化活性中心的鋅離子結(jié)合而抑制其催化活性[7]。本實(shí)驗(yàn)通過研究川芎嗪對hpmcs在高糖刺激下主要ecm ⅰ型膠原及其降解酶系mmp?1/timp?1分泌及表達(dá)的影響,旨在探討川芎嗪對hpmcs在高糖環(huán)境下ⅰ型膠原的合成和降解的干預(yù)作用及其機(jī)制。結(jié)果顯示,川芎嗪能顯著降低高糖所致的ⅰ型膠原的過度合成,同時(shí)顯著下調(diào)timp?1的表達(dá),增加mmp?1的表達(dá),提示川芎嗪亦能通過調(diào)節(jié)mmp?1/timp?1的平衡,從而促進(jìn)ⅰ型膠原的降解,減少ecm沉積。由此我們推測,川芎嗪可能具有預(yù)防或延緩腹膜纖維化的作用。
川芎嗪是中藥川芎的有效成分之一,屬酰胺類生物堿,具有活血化瘀的功效。藥理實(shí)驗(yàn)證明,川芎嗪具有擴(kuò)張血管、改善微循環(huán)、調(diào)節(jié)免疫和鈣離子拮抗的作用[8]。目前川芎嗪抑制ⅰ型膠原、timp?1和增加mmp?1表達(dá)的機(jī)制尚不清楚。以往的研究發(fā)現(xiàn)這可能與抑制轉(zhuǎn)化細(xì)胞生長因子β1(transforming growth factor?β1, tgf?β1)表達(dá)有關(guān)[9, 10]。tgf?β1是重要的致纖維化細(xì)胞因子,參與了腹膜纖維化的病理過程[2]。tgf?β1可增加ⅰ型膠原的合成,并且抑制mmps的活性而激活timps,使ⅰ型膠原降解減少[3, 11]。有研究報(bào)道,川芎嗪能降低多種細(xì)胞如心肌細(xì)胞、肝細(xì)胞和血管內(nèi)皮細(xì)胞的膠原合成和timp?1表達(dá),而增加mmp?1的分泌和表達(dá),進(jìn)一步的研究發(fā)現(xiàn)這可能是通過抑制tgf?β/smads信號傳導(dǎo)通路繼而抑制tgf?β1表達(dá)的結(jié)果[9, 10, 12]。我們前期研究證實(shí),川芎嗪能下調(diào)高糖致hpmcs tgf?β1的表達(dá)(文章待發(fā)表)。因此我們推測,川芎嗪抑制tgf?β1的表達(dá)可能是其抑制hpmcs ⅰ型膠原合成和調(diào)整mmp?1/timp?1表達(dá)平衡的機(jī)制之一,其具體機(jī)制將是我們下一步要研究的內(nèi)容。
綜上所述,川芎嗪能抑制高糖致hpmcs ⅰ型膠原的過度合成,并且通過調(diào)節(jié)mmp?1/timp?1的平衡,促進(jìn)ⅰ型膠原降解,從而減少ecm的沉積,防止腹膜纖維化的發(fā)生和發(fā)展。因此,川芎嗪可能具有預(yù)防或延緩腹膜纖維化的作用,這對腹膜纖維化的機(jī)制及其防治的研究有一定借鑒和應(yīng)用價(jià)值。
【參考文獻(xiàn)】
1 plum j, hermann s, fussh?ller a, schoenicke g, donner a, r?hrborn a, grabensee b. peritoneal sclerosis in peritoneal dialysis patients related to dialysis settings and peritoneal transport properties. kidney int suppl. 2001; 78: s42?s47.
2 yung s, liu zh, lai kn, li ls, chan tm. emodin ameliorates glucose?induced morphologic abnormalities and synthesis of transforming growth factor beta1 and fibronectin by human peritoneal mesothelial cells. perit dial int. 2001; 21(suppl 3): s41?s47.
3 kim jj, li jj, kim ks, kwak sj, jung ds, ryu dr, yoo th, choi hy, han sh, kim hj, yoon sy, han ds, kang sw. high glucose decreases collagenase expression and increases timp expression in cultured human peritoneal mesothelial cells. nephrol dial transplant. 2008; 23(2): 534?541.
4 perfumo f, altieri p, degl'innocenti ml, ghiggeri gm, caridi g, trivelli a, gusmano r. effects of peritoneal effluents on mesothelial cells in culture: cell proliferation and extracellular matrix regulation. nephrol dial transplant. 1996; 11(9): 1803?1809.
5 wang yd, yan py. expression of matrix metalloproteinase?1 and tissue inhibitor of metalloproteinase?1 in ulcerative colitis. world j gastroenterol. 2006; 12(37): 6050?6053.
6 visse r, nagase h. matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. circ res. 2003; 92(8): 827?839.
7 fujisaki k, tanabe n, suzuki n, mitsui n, oka h, ito k, maeno m. the effect of il?1alpha on the expression of matrix metalloproteinases, plasminogen activators, and their inhibitors in osteoblastic ros 17/2.8 cells. life sci. 2006; 78(17): 1975?1982.
8 huang y, chen sq, zhang g, chen rh. effect of tetromethylpyrazine and aminoguanidine on expression of vascular endothelial growth factor in kidney of diabetic rats. j chin integr med. 2004; 2(1): 39?41. chinese with abstract in english.
黃焱, 陳少強(qiáng), 張更, 陳瑞華. 川芎嗪聯(lián)合氨基胍對糖尿病大鼠腎臟血管內(nèi)皮細(xì)胞生長因子表達(dá)的影響. 中西醫(yī)結(jié)合學(xué)報(bào). 2004; 2(1): 39?41.
9 lin yz, xu cx, deng yl, chen l, huang h, du j. effects of tetramethylpyrazine on fibrosis of atrial tissue and atrial fibrillation in a canine model of congestive heart failure induced by ventricular tachypacing. j chin integr med. 2006; 4(1): 35?38. chinese with abstract in english.
林亞洲, 許春萱, 鄧玉蓮, 陳林, 黃海, 杜建. 川芎嗪對心室快速起搏心力衰竭實(shí)驗(yàn)犬心房顫動及心房纖維化的影響. 中西醫(yī)結(jié)合學(xué)報(bào). 2006; 4(1): 35?38.
10 hua hy, li yy, ge sw. study of tetramethylpyrazine in treatment on liver fibrosis and mechanism in rats. zhong yao yao li yu lin chuang. 2007; 23(5): 60?62. chinese with abstract in english.
華海嬰, 李艷瑛, 戈士文. 川芎嗪抗大鼠免疫損傷性肝纖維化作用及機(jī)制研究. 中藥藥理與臨床. 2007; 23(5): 60?62.